Cybin (CYBN.NE) announced that the Institutional Review Board (IRB) has granted them approval to begin the study of its sublingual psilocybin formulation, CYB001, in a Phase II clinical trial…
Latest News
Are stock markets about to crash hard?
Revive Therapeutics (RVV.CN) announces FDA acceptance of meeting request
Top 5 Gainers and Losers: LAC.TO, WEED.TO, OML.V
BC Bud Corp (BCBC.C) breathes new life into the cannabis space, up 3x in two months
Top 5 Gainers and Losers: TMQ.TO, GLM.CN, AGMR.V
Standard Uranium (STND.V) reports on exploration at Sun Dog Project